Tau seeding in cases of multiple sclerosis.
FRET biosensor
Multiple sclerosis
Tau seeding activity, tau, prion, propagation, neurodegeneration
Tauopathy
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
24
06
2022
accepted:
08
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Relapsing remitting multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system that in many cases leads to progressive MS, a neurodegenerative disease. Progressive MS is untreatable and relentless, and its cause is unknown. Prior studies of MS have documented neuronal accumulation of phosphorylated tau protein, which characterizes another heterogeneous group of neurogenerative disorders, the tauopathies. Known causes of tauopathy are myriad, and include point mutations within the tau gene, amyloid beta accumulation, repeated head trauma, and viral infection. We and others have proposed that tau has essential features of a prion. It forms intracellular assemblies that can exit a cell, enter a secondary cell, and serve as templates for their own replication in a process termed "seeding." We have previously developed specialized "biosensor" cell systems to detect and quantify tau seeds in brain tissues. We hypothesized that progressive MS is a tauopathy, potentially triggered by inflammation. We tested for and detected tau seeding in frozen brain tissue of 6/8 subjects with multiple sclerosis. We then evaluated multiple brain regions from a single subject for whom we had detailed clinical history. We observed seeding outside of MS plaques that was enriched by immunopurification with two anti-tau antibodies (HJ8.5 and MD3.1). Immunohistochemistry with AT8 and MD3.1 confirmed prior reports of tau accumulation in MS. Although larger studies are required, our data suggest that progressive MS may be considered a secondary tauopathy.
Identifiants
pubmed: 36221144
doi: 10.1186/s40478-022-01444-2
pii: 10.1186/s40478-022-01444-2
pmc: PMC9552360
doi:
Substances chimiques
Amyloid beta-Peptides
0
Prions
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Subventions
Organisme : NIA NIH HHS
ID : RF1 AG059689
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Neuron. 2016 Nov 23;92(4):796-812
pubmed: 27974162
Mol Ther. 2022 Apr 6;30(4):1484-1499
pubmed: 35007758
Acta Neuropathol Commun. 2021 May 26;9(1):99
pubmed: 34039426
Brain Pathol. 2015 May;25(3):350-64
pubmed: 25904048
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8187-E8196
pubmed: 27911827
Neuropathol Appl Neurobiol. 1994 Apr;20(2):103-10
pubmed: 8072641
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Clin Neuropathol. 1996 Jan-Feb;15(1):22-5
pubmed: 8998852
Acta Neuropathol. 2009 May;117(5):583-9
pubmed: 19288121
Elife. 2018 Jul 10;7:
pubmed: 29988016
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376-85
pubmed: 25261551
Nat Rev Neurol. 2012 Nov 5;8(11):647-56
pubmed: 23007702
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Acta Neuropathol. 2010 May;119(5):591-600
pubmed: 20306268
Acta Neuropathol. 2018 Nov;136(5):691-697
pubmed: 30219940
Acta Neuropathol. 2021 Jul;142(1):57-71
pubmed: 33830330
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neuron. 2014 Jun 18;82(6):1271-88
pubmed: 24857020
Acta Neuropathol Commun. 2021 Nov 2;9(1):177
pubmed: 34727983
Brain. 2008 Jul;131(Pt 7):1736-48
pubmed: 18567922
Nature. 2021 Oct;598(7880):359-363
pubmed: 34588692
Front Neurosci. 2018 Apr 24;12:267
pubmed: 29740275
Mult Scler. 2020 Jul;26(8):876-886
pubmed: 31682184
Neuron. 1999 Nov;24(3):507-10
pubmed: 10595503
Ann Neurol. 1997 Sep;42(3):356-9
pubmed: 9307257
Lancet Neurol. 2021 Jun;20(6):470-483
pubmed: 33930317